Alvesco (ciclesonide) is an inhaled corticosteroid with novel release and distribution properties that result in lung-targeted anti-inflammatory effects. The product is currently approved in 35 countries worldwide for
King is set to pay up to $110 million for rights to current and future new drug applications held by Arrow regarding novel formulations of Altace. The agreements
Scavidin was used to target and concentrate intravenous doses of as little as one-tenth the conventional levels of the radioisotope Yttrium(90) in one model, and the chemotherapy drug
The project, which is funded by the German Federal Ministry of Education and Research, is focusing on the properties of nanoparticles to ensure that they pose no risk
The study in colorectal cancer is being conducted to determine whether survival is prolonged in patients with metastatic colorectal cancer treated with Erbitux in combination with the chemotherapeutic
Such adverse events have been reported in cancer patients receiving systemic administration of a pan-VEGF inhibitor, with a greater incidence in patients over 65 years of age. “The
The Australian National University (ANU) was one of the various academic institutions to benefit from the funding. Researchers at the ANU College of Medicine and Health Sciences have
The multicenter study will compare Nexavar when co-administered with the chemotherapeutic agents versus the chemotherapeutic agents alone. The study, which is expected to enroll approximately 900 patients, will
The programs aim to develop and bring to market a variety of new and promising nutritional products. Investors in this round of financing include both new and existing
Chemokine Therapeutics has entered into a material transfer agreement to supply Dana-Farber with CTCE-9908, a chemokine CXCR4 antagonist. Oncologists at the institute will study the benefits of CTCE-9908
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.